Hacker News Reader

A GLP-1 drug trial 12 years ago by a major pharma company was stopped because of increased suicide risk (2 in 10,000) among the cohort.

We will see what happens long term the second time around.

View on HN

"Compared with those prescribed lifestyle intervention for obesity, adolescents prescribed either liraglutide (Saxenda; Novo Nordisk) or semaglutide (Wegovy; Novo Nordisk) had a 33% lower risk of suicidality over 12 months of follow-up after controlling for potential baseline confounders."[1]

[1]https://www.tctmd.com/news/defying-earlier-glp-1-data-study-...

It's not even the second time around now, liraglutide was approved a decade ago.

Reply on news.ycombinator.com